Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Posters

Search Title by author or title

Endothelial keratoplasty: a prospective study of 34 cases, two year follow-up

Poster Details

First Author: S.Leboukhe ALGERIA

Co Author(s):    L. Degded   S. Alaeddine   A. Hichem              

Abstract Details

Purpose:

2 years' review of endothelial keratoplasty procedures: Descemet stripping Automated endothelial keratoplasty (DSAEK) and Descemet's membrane endothelial keratoplasty (DMEK) for endothelial corneal diseases: pseudophakic bullous Keratopathy (PBK), Aphakic bullous keratopathy (ABK), Cornea Graft Failure (CGF) and Fuchs' endothelial dystrophy (FD). Data on visual acuity, DASEK graft thickness, complication rates and endothelium cell loss were investigated.

Setting:

A single-center: Military University Hospital of Constantine, Algeria (2017-2019).

Methods:

A prospective interventional cohort of 34 eyes of 33 patients suffered from Bullous keratopathy surgically treated by endothelial keratoplasty (30 DSAEK,4 DMEK) from January 2016- February 2019. DSAEK grafts was prepared using microkeratome (Moria, Antony, France) with single pass. DMEK grafts were prepared using Scuba technique.

Results:

Mean age is 72,33 ± 9,76 years. Female 52,9%, Male 47,1%. 82,4% patients suffered from PBK, 8,7% CGF.5,9% ABK and 2,9% FD. 8,9% underwent combined surgery. The mean astigmatism is 1,98 ± 0,66 D. The mean BSCVA in Log Mar pre and postoperative respectively is 1,43 ± 0,15, 0,55 ± 0,07 (p < 0,001). 88,9% have their BSCVA > 0,5. BSCVA (DMEK) > BSCVA (DSAEK) (p <0,001). 79,2% ultrathin DSAEK was obtained. ECD at 01year and 02 years respectively is (20,47%, 35,19%).17,7% graft detachment was re-bubbled successfully, one DMEK detachment failed. No graft rejection occurred.

Conclusions:

EK procedures allow fast visual rehabilitation, anterior ocular surface preservation and preserve from high endothelial cell loss. In the case of DSAEK, new microkeratomes are more predictable and permit to achieve high rate of ultrathin DASEK.

Financial Disclosure:

None

Back to Poster listing